Working with a shared voice can be very effective for improving outcomes in the Movement Disorders clinic, finds Dr. Martin McKeown and Parkinson’s research coordinator Kristen Sundvick. For some people with Parkinson’s disease (PD), even optimal drug treatments simply aren’t as effective as they need to be. On conventional medication, people may fluctuate unpredictably between being unable to move, to…
Read More
My team focuses on development of novel innovative technology for cancer therapeutics and diagnostics. A major focus of the lab is on the identification of oncofetal proteins and secondary protein modifications such as glycosylation’s that can be potentially exploited as cancer targets in the clinic. We are more technology focused than disease focused in the sense that we are generally...
Read More
Dr. Leonard Foster – Winner of the Genome British Columbia Award for Scientific Excellence at the 2017 Life Science BC Awards. CIHR Funding Decisions Dr. Julio Montaner CIHR Gold Leaf Prize for Impact Read More Centre for Epigenome Mapping Technologies (CEMT) CEEHRC Phase II: Platform Centres Renewal Read More Dr. Winson Cheung Operating Grant: Analyses of Existing Canadian Cohorts and…
Read More
In Steven Soderbergh’s classy television show The Knick, set in a New York City hospital in the early 1900s, competitive and obsessively driven surgeon-scientists work on the burning medical issues of the day — identification of blood groups to allow blood transfusions, for example, and facial reconstruction surgery that returns dignity to those disfigured by syphilis. Would-be healers have been testing surgical…
Read More
People with multiple sclerosis can show signs of something wrong five years before the onset of disease, much earlier than previously thought, according to a new analysis of health records from people with the condition. The new research, published today in Lancet Neurology, is a first step to identifying red flags to help doctors screen for the disease and start…
Read More
A drug created from a malaria protein stopped tumour growth of chemotherapy-resistant bladder cancer, offering hope for cancer patients not responding to standard treatments. “This is the first study where we put the concept of using malaria proteins for cancer therapy into a direct clinical context,” said Mads Daugaard, an assistant professor of urologic science at the University of British…
Read More
 DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced a proposed registered public offering of its common stock and warrants to purchase common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering…
Read More
An early report on the molecular subtyping of muscle-invasive bladder cancer (MIBC) by gene expression suggested that response to neoadjuvant chemotherapy (NAC) varies by subtype. To investigate the ability of molecular subtypes to predict pathological downstaging and survival after NAC. Whole transcriptome profiling was performed on pre-NAC transurethral resection specimens from 343 patients with MIBC. Samples were classified according to four published…
Read More